Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Long-Term Deferred Tax: 2019-2024

Historic Long-Term Deferred Tax for Pharming Group N.V (PHAR) over the last 6 years, with Dec 2024 value amounting to $30.5 million.

  • Pharming Group N.V's Long-Term Deferred Tax fell 25.21% to $27.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.5 million, marking a year-over-year decrease of 25.21%. This contributed to the annual value of $30.5 million for FY2024, which is 2.63% up from last year.
  • Per Pharming Group N.V's latest filing, its Long-Term Deferred Tax stood at $30.5 million for FY2024, which was up 2.63% from $29.8 million recorded in FY2023.
  • Over the past 5 years, Pharming Group N.V's Long-Term Deferred Tax peaked at $30.5 million during FY2024, and registered a low of $31,877 during FY2020.
  • Its 3-year average for Long-Term Deferred Tax is $27.8 million, with a median of $29.8 million in 2023.
  • In the last 5 years, Pharming Group N.V's Long-Term Deferred Tax slumped by 99.90% in 2020 and then spiked by 66,455.82% in 2021.
  • Yearly analysis of 5 years shows Pharming Group N.V's Long-Term Deferred Tax stood at $31,877 in 2020, then surged by 66,455.82% to $21.2 million in 2021, then climbed by 8.28% to $23.0 million in 2022, then climbed by 29.55% to $29.8 million in 2023, then rose by 2.63% to $30.5 million in 2024.